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ABSTRACT Understanding protein phase behavior is important for puriﬁcation, storage, and stable formulation of protein drugs in
the biopharmaceutical industry. Glycoproteins, such as monoclonal antibodies (MAbs) are the most abundant biopharmaceut-
icals and probably the most difﬁcult to crystallize among water-soluble proteins. This study explores the possibility of correlating
osmotic second virial coefﬁcient (B22) with the phase behavior of an intact MAb, which has so far proved impossible to crys-
tallize. The phase diagram of the MAb is presented as a function of the concentration of different classes of precipitants, i.e., NaCl,
(NH4)2SO4, and polyethylene glycol. All these precipitants show a similar behavior of decreasing solubility with increasing
precipitant concentration. B22 values were also measured as a function of the concentration of the different precipitants by self-
interaction chromatography and correlated with the phase diagrams. Correlating phase diagrams with B22 data provides useful
information not only for a fundamental understanding of the phase behavior of MAbs, but also for understanding the reason why
certain proteins are extremely difﬁcult to crystallize. The scaling of the phase diagram in B22 units also supports the existence of
a universal phase diagram of a complex glycoprotein when it is recast in a protein interaction parameter.
INTRODUCTION
A protein solution remains homogenous only up to a certain
protein concentration. Once this solubility limit is exceeded,
a new state or phase appears as a result of different mech-
anisms such as crystallization, precipitation, gelation, ag-
gregation, or liquid-liquid phase separation. These phase
transformations in a protein solution are generally deﬁned as
‘‘phase behavior’’. Understanding protein phase behavior is
important for a variety of reasons. From a medical point of
view, protein phase transition is the cause of many diseases,
such as cataracts (1), Sickle-cell diseases (2), and neurode-
generative or amyloidogenic diseases (3,4). The controlled
release of certain protein drugs, such as insulin, depends on
their particular state (5). From a biological perspective, the
microcompartmentation of the cell cytoplasm is thought to
be driven partially by protein phase separation (6).
Protein crystallization, on the other hand, is an important
tool of structural biology. Most high-resolution protein struc-
tural information is obtained by x-ray diffraction, neutron
crystallography, or surface plasmon resonance of protein crys-
tals. Protein crystallization is also instrumental in elucidating
protein function, mode of action, reaction mechanism, and so
on. In addition, precipitation and crystallization are impor-
tant unit operations in the puriﬁcation of industrial proteins
and are receiving increasing attention in the industrial sep-
aration of therapeutic proteins. Salt-induced precipitation is
often the ﬁrst step in protein puriﬁcation from a fermentation
broth, or from plant and animal extracts, whereas crystalli-
zation may be the last. Solid (crystal or precipitate) forms of
a protein are also convenient for storage and transportation.
Furthermore, the stability of a biologically active protein is
well maintained in the crystal form.
The quality of crystals may not be an important issue when
crystallization is applied for puriﬁcation and/or storage of
protein. It is, rather, important to obtain crystals in bulk
quantity without losing protein functionality. However, struc-
tural elucidation by x-ray crystallography requires diffraction-
quality crystals. Growing such crystals has always been the
major barrier to the crystallographic determination of protein
structure, in particular in the case of integral membrane pro-
teins (7) and glycoproteins (8). Membrane proteins are gen-
erally considered to be the most difﬁcult to crystallize, mainly
due to their amphiphilic character, which implies the use of
detergent for their solubilization and crystallization (9). Among
water-soluble proteins, glycoproteins are considered the most
difﬁcult to crystallize (10).
Monoclonal antibodies (MAbs) are ﬂexible macromole-
cules that can assume a wide range of conformations as a
consequence of their intrinsic domain mobility and segmen-
tal ﬂexibility. MAbs have recently been recognized as enor-
mously efﬁcacious therapeutics, which can be applied to treat
numerous life-threatening diseases, including cancer and im-
mune diseases. MAbs are also well established as speciﬁc
serologic reagents for a number of immunoassays and diag-
nostics for the detection of a wide variety of antigens thanks
to their unlimited availability (11). Unfortunately, MAbs are
extremely difﬁcult to crystallize as intact molecules, prob-
ably because of their structural complexity and variability.
Most of the published MAb crystallization experiments have
been restricted to either Fab-antigen complexes or MAb
fragments or MAbs without a hinge region. Nevertheless,
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successful crystallization of intact MAbs has been reported
on several occasions (10,12–16). However, successful crystal-
lization of one MAb obviously does not imply that other
MAbs will equally readily crystallize under the same solution
conditions.
Crystallization or, more generally, transformation into dif-
ferent phases of a protein, occurs due to changes in solution
conditions. There are numerous solution variables that can
inﬂuence protein phase behavior (17), and a variety of phases
may form that are difﬁcult to distinguish. The changes of state
of a protein as a function of these solution variables are gen-
erally known as a ‘‘protein phase diagram’’. The fundamen-
tal relationship between a particular solution condition and
a particular state of protein is poorly understood. However,
evidence has been accumulating that protein interactions play
a governing role in determining the structure of the phase
diagram. The most tangible result so far is that the phase
behavior of a protein solution is correlated with a protein-
interaction parameter named ‘‘osmotic second virial coefﬁ-
cient’’ (B22). B22, by deﬁnition, is a thermodynamic parameter
that reﬂects the magnitude and direction of deviations of a
protein solution from ideality. At the molecular level, B22
characterizes pairwise protein self-interactions including con-
tributions from excluded volume, electrostatic interactions,
and short-range interactions (18). According to statistical ther-
modynamics, B22 is correlated to the potential of mean force,
which describes all known interactions between two protein
molecules in a dilute solution (19). A negative value of B22
indicates protein-protein attraction, whereas a positive B22
value indicates mutual repulsion.
Solution conditions under which a protein is likely to crys-
tallize correspond to a certain range of slightly negative B22
values, known as the ‘‘crystallization slot’’ (20,21). If a B22
value is more negative than the crystallization slot, dis-
ordered precipitation is the phase most likely to develop.
However, conducting crystallization experiments under con-
ditions that correspond to the crystallization slot does not
guarantee a successful crystallization. The predictive value
of the crystallization slot can be improved by studying spe-
ciﬁc ion effects and the phase diagram. On the other hand,
conducting experiments under conditions corresponding to
positive B22 values is sure to prevent phase separation from
occurring. This correlation is also exploited in pharmaceu-
tical industries for screening stable conditions, at which B22
values are largely positive, e.g., for liquid formulations of
protein drugs. A detailed review of B22 values of different
proteins and their corresponding phases was published earlier
(22,23). The thermodynamic insight regarding the macromo-
lecular interactions involved in B22 (18,24) and why these
interactions are related to protein phase behavior were ex-
plained elsewhere (25–28).
Besides being related to the crystallization slot, it has been
established that B22 is a critical parameter in controlling or ac-
celerating protein aggregation, folding, and stability (29–31).
Recent studies show that B22 is an important thermodynamic
parameter not only in predicting protein phase behavior, but
also in understanding and designing a molecular approach to
different bioseparation processes (32–36). The reason B22
was not applied to bioseparations earlier is because of the
difﬁculty of experimentally determining B22. The recent de-
velopment of self-interaction chromatography (SIC) allows
more accurate and rapid measurement of B22 using a minimal
amount of protein (22,23,37–45).
This study explores the correlation between B22 and the
phase behavior of an intact monoclonal antibody, designated
in this article as IDEC-152, which has a molecular mass of
;144 kDa. The IDEC-152 MAb has not been possible to
crystallize as yet, even when commercial crystallization kits
particularly designed for intact MAbs were employed. The
unsuccessful crystallization efforts on IDEC-152 prompted a
study of its phase behavior with respect to B22 values. In this
article, we present phase diagrams of IDEC-152 as a function
of different classes of precipitants. B22 values were also mea-
sured for the same conditions by SIC and correlated with the
phase diagrams. As a result, a single MAb phase diagram dis-
plays solubility, B22, and the optimal crystallization region.
This phase diagram is useful not only in developing a fun-
damental understanding of the phase behavior of MAbs, but
also in understanding the reason why certain proteins are ex-
tremely difﬁcult to crystallize. To the best of our knowledge,
this is the ﬁrst work to present experimental data on phase
behavior of an intact MAb. In addition, the scaling of the
phase diagram in B22 units provides useful information on a
structurally complex glycoprotein, demonstrating the uni-
versality of the phase diagram of many proteins when recast
in a protein interaction parameter.
PROTEIN PHASE DIAGRAM
A phase diagram shows the state of a material as a function
of all of the relevant variables of the system. The simplest
form of a protein phase diagram usually displays the state of
a protein as a function of protein concentration and another
parameter, i.e., the precipitant concentration, with all other
variables held constant. This simple phase diagram of dif-
ferent proteins under different solution conditions is quan-
titatively quite different, although their basic shape is similar.
Many broad classes of proteins display a single universal
phase diagram, if the phase diagram is recast on a protein
interaction parameter (25–27,33,46,47), instead of correlat-
ing a single parameter with a solution condition. This is not
surprising, because a protein interaction parameter, such as
B22, reﬂects all the solution parameters in a single dimension.
Once B22 values of a protein are known, the approximate
shape and position of the phase diagram would be known.
Rosenbaum and co-workers (25–27) pioneered the devel-
opment of a generalized protein phase diagram based on
its similarity to those of colloids immersed in polymer
solutions. They showed that proteins and other globular
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macromolecules with a size.1 nm do not display gas-liquid
phase transitions (25), but rather display a broad region of
metastable liquid-liquid coexistence along with the region of
the liquid-crystal solubility line. In other words, the protein
phase diagram exhibits only a liquid-solid equilibrium in
three distinct phases: a dilute liquid phase (analogous to the
vapor phase), a dense liquid phase (analogous to the liquid
phase), and a crystal phase (analogous to the solid phase). The
liquid-liquid coexistence region in a protein phase diagram is
further separated into two parts (Fig. 1), a metastable liquid-
liquid region referred to as the ‘‘binodal’’ and an unstable
liquid-liquid region referred to as the ‘‘spinodal’’ (51–53). If
a protein solution is quenched into the spinodal of this liquid-
liquid phase transition, the solution will spontaneously sepa-
rate into two metastable phases corresponding to the binodal,
i.e., one light phase depleted in protein and the other dense
phase concentrated in protein. In the regions between the
binodal and the spinodal curves, the solution is metastable
with respect to liquid-liquid phase separation, i.e., liquid-
liquid phase separation occurs rather slowly in these regions.
At the critical point, the two phases become identical, and
liquid-liquid phase separation is not possible beyond this
point.
The location of George and Wilson’s crystallization slot
(20,21) in the universal protein phase diagram is around the
metastable liquid-liquid immiscibility region (33,47,51,52).
The precise location of the crystallization is below the liquid-
liquid critical point (27,47) as well as around the critical point
(54–57), where nucleation occurs by two different mechanisms.
Because of the presence of a nearby metastable liquid-liquid
two-phase region, critical density ﬂuctuations are strongly
enhanced around the liquid-liquid critical point, which lowers
the free energy barrier to the formation of critically sized
nuclei (55–57). Therefore, nucleation occurs around the crit-
ical point spontaneously. Below the critical point, small
liquid-like droplets with a density corresponding to the dense
branch of the liquid-liquid binodal may lead to the en-
hancement of nucleation just outside the low-density branch
of the liquid-liquid binodal (51,58). As a consequence of the
high concentration in the droplets, a large fraction of the pro-
tein molecules forms aggregates. Crystalline nuclei are then
formed from the aggregates inside the droplets. Once the
aggregate grows beyond a critical size (about a few hundred
molecules), it can convert into a stable crystalline nucleus
(59). Each nucleus is covered with a thin liquid ﬁlm with a
high protein concentration. This thin ﬁlm lowers the surface
energy of the crystal. Protein molecules, diffusing from the
dilute solution to the crystal are ﬁrst incorporated into the
surface ﬁlm. The molecules in this liquid surface ﬁlm are
quite mobile and have ample time to ﬁnd the proper ori-
entation for incorporation into the crystal (53). If protein so-
lution conditions fall within the spinodal, the formation of
large droplets of high density is favored over the formation
of crystalline nuclei. The rapid phase separation in this re-
gion leaves little time for establishing the proper order and
steric orientations of the protein molecules required for crys-
tallization. The desolubilization and self-association rate are
faster in this region than the rate at which molecules achieve
the proper orientations that would favor crystallization. Be-
low George andWilson’s crystallization slot, the binodal and
spinodal are so wide that the light branches of both binodal
and spinodal correspond to an impractically low concen-
tration of protein to induce crystallization. Therefore, this
region favors amorphous precipitation rather than crystalli-
zation.
George and Wilson’s narrow range of B22 values provides
necessary but insufﬁcient information for successfully pre-
dicting crystallization of different proteins. The universal
protein phase diagram in the dimension of B22 gives further
insight into the possibility of crystallizing a protein that is
difﬁcult to crystallize, such as IDEC-152. For instance, nu-
cleation can occur more easily when there is a larger distance
between the liquid-liquid critical point and the liquid-solid
solubility line (26). However, the phase behavior of certain
proteins may not be precisely mapped using the universal
phase diagram because of the presence of long-range inter-
actions and/or the highly anisotropic nature of protein inter-
actions occurring due to nonsphericity and surface patchiness.
For example, a protein solution well between the critical
point and the solubility line might also prove to be difﬁcult
to crystallize because of its noncomplementary shape (24).
Certain proteins may have a strong mutual attraction in a few
speciﬁc orientations, which lead to overall slightly negative
B22 values but are not compatible with any solid lattice for-
mation. If all the bonds necessary for crystallization cannot
form in the crystalline phase, but only in the liquid phase,
then the protein will not crystallize. Rather, it will exist as
a condensed liquid state, analogous to the precipitate phase
(54,60). The presence of moderately long-range interactions,
FIGURE 1 Schematic representation of a generalized protein phase
diagram.
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which are generally neglected, would shift the liquid-liquid
critical point to the gelation regime (61–63).
MATERIALS AND METHODS
Materials
IDEC-152 MAb was provided by Biogen-Idec (San Diego, CA). N-hydroxy-
succinimide (NHS)-activated Sepharose 4 Fast Flow (code 17-0906-01), a
Tricorn 5/50 column (code 18-1163-09), and a Tricorn 5 adaptor unit (code
18-1153-00) were purchased from GE Healthcare Europe, Diegem, Belgium.
Acetic acid (Baker analyzed, product 6052), sodium chloride (Baker ana-
lyzed, product 0278), hydrochloric acid (36–38%, Baker analyzed, product
6081), acetone (Bakers HPLC analyzed, product 8142), and sodium hydrox-
ide (Baker analyzed, pellets, product 0402) were bought from Mallinckrodt
Baker (Deventer, The Netherlands). Sodium hydrogen phosphate dihydrate
(product 1.06573), sodium dihydrogen phosphate dodecahydrate (product
1.06345), ammonium sulfate (extra pure, product 1.01216), and sodium ac-
etate trihydrate (extra pure, product 1.06265) were bought from Merck
(Darmstadt, Germany). Ethanolamine (redistilled, product 41100), blue dex-
tran (product D5717), and polyethylene glycol (PEG) 400 (product 81170)
were bought from Sigma-Aldrich Chemie (Zwijndrecht, The Netherlands).
Bicinchoninic acid protein assay reagents (products 23221 and 23224) were
bought from Perbio Science Nederland (Etten-Leur, The Netherlands).
Dialysis equipment was a Spectra/Por Float-A-Lyzer with biotech cellu-
lose ester membranes, 100 kDa nominal molecular weight cutoff (NMWCO),
10 ml; (product 235071, Spectrum Europe, Breda, The Netherlands). A
Centriprep centrifugal ﬁlter unit (15 ml, 3 kDa NMWCO, catalog 4303) was
from Millipore (Amsterdam, The Netherlands). Chromatography experiments
were done in a Pharmacia (Uppsala, Sweden) fast protein liquid chroma-
tography system controlled by Unicorn version 2.0 software. All spectro-
photometric analysis was done in a UV-Visible Pharma System (8453,
Agilent, Santa Clara, CA).
MAb sample preparation
The IDEC-152 MAb was prepared for SIC and precipitation experiments
by dialysis using a 100-kDa NMWCO membrane at 4C for at least 24 h.
Dialysis results in an approximately twofold dilution of the MAb solution.
The dialyzed MAb solution was further diluted or concentrated according to
the requirement.
Self-interaction chromatography
Two different columns, one with immobilized MAb Sepharose particles and
the other MAb-free Sepharose particles, were packed for SIC. TheMAb-free
column was prepared simply by blocking the NHS-activated groups of the
Sepharose particles with ethanolamine. The immobilized MAb column was
prepared by immobilizing MAb on NHS-activated sepharose particles. The
details of the column preparation processes were described earlier (22,23).
The concentration of immobilized MAb per volume of gel particles was
determined by the bicinchoninic acid technique (64) applied to the solid
phase (22,23,65). The integrity of the packed column was characterized by
analyzing its height equivalent to a theoretical plate, peak shape, and sym-
metry of a small molecule, such as acetone and NaCl. When not in use, the
columns were stored in 10 mM sodium phosphate (pH 7.0) at 4C. Each
column was used for a period of maximally 4 weeks.
The chromatography procedure was accomplished as described previ-
ously (37) in an automated Pharmacia fast protein liquid chromatography
system controlled by Unicorn version 2.0 software. Before every injection,
the column was equilibrated until the UV, pH, and conductivity base lines
became stable. The retention data were used for calculating the B22 values
according to Ahamed et al. (22,23).
Determination of phase diagram
The phase diagram of the IDEC-152 MAb was determined as a function of
different precipitant concentrations at a constant temperature of 30C. The
precipitants used in this study were NaCl, (NH4)2SO4, and PEG-400. Since
the MAb was only available in liquid form and no crystallization of this
MAb was possible, its solubility or phase diagram was measured from
precipitation experiments. The dialyzed MAb solution was concentrated to
150 mg/ml at pH 7.6 (10 mM Na-phosphate). Then a 3.0 M (NH4)2SO4
solution (pH 7.6, 10 mM Na-phosphate) was added drop-by-drop on an
analytical balance to 1 ml of a 150 mg/ml MAb solution until phase
separation was visually observed. The minimum (NH4)2SO4 concentration
at which the MAb solubility was ;100 mg/ml was considered the starting
point. On the other hand, the minimum (NH4)2SO4 concentration at which
the addition of a single drop of a 1 mg/ml MAb solution into 1 ml of an
(NH4)2SO4 solution caused phase separation was regarded as the end point.
Several points were chosen between the start and the end point. At every
point, the MAb solutions were diluted to a number of different concentra-
tions and incubated for 48 h to reach a stable supernatant concentration. The
solutions were then investigated at 600 nm in a spectrophotometer to con-
ﬁrm the existence of phase separation. Finally the MAb concentration in the
supernatant was measured. The concentration of MAb in the supernatant
phase was treated as its apparent solubility. On the other hand, the maximum
MAb concentration at which no phase separation was observed was iden-
tiﬁed as a point on the precipitation line. To determine the precipitate concen-
tration, the solutions were allowed to settle under gravity and supernatants
were removed gently.
Modeling of protein phase diagram
The phase diagram of the MAb was generated in B22 scale according to Haas
and Drenth (51–53). According to their model, the Gibbs free energy per unit
volume of a protein solution can be expressed as (51)
GlðfÞ ¼ 1
V
f
2
fc
 
gl1 kTfln
f
m
 
 kT f 6f
21 4f3
ð1 fÞ2
  
:
(1)
In Eq. 1, f is the volume fraction of protein, V is the volume of a protein
molecule, fc is the protein volume fraction in the crystal, and m ¼ V=v;
where v is the molar volume of water divided by Avogadro’s number. The
parameter for a protein-protein interaction in solution, gl; was calculated as
gl ¼ kTfc B22Mr  4ð Þ; where M is the molecular mass of protein and r is
the protein density. In the calculations, the volume of an intact MAb
molecule, V; was assumed as 166.5 nm3, considering the fact that the unit
cell volume (2 molecules/unit cell) of the MAb crystals was 900 nm3 (14), in
which the MAb volume fraction, fc; was 0.37 (66). This resulted in the
value r ¼ 1.44 g/cm3, considering the molecular mass of the IDEC-152
MAb, M, of 144 kDa.
The compositions of the two coexisting liquid phases in the binodal (fa
and fb) were calculated from the following equations:
GlðfbÞ  GlðfaÞ ¼ fb
@Gl
@f
 
fb
fa
@Gl
@f
 
fa
(2)
ð@Gl=@fÞfb ¼ ð@Gl=@fÞfa : (3)
Similarly, the compositions of the phases in the spinodal (fa
 and fb) were
calculated from the conditions @2Gl=@f
2
 	
fa
¼ 0 and @2Gl=@f2
 	
fb
¼ 0:
For the calculation of solubility, the Gibbs free energy per unit volume of
protein crystal was expressed as Gc ¼ fcgc=V; where gc ¼ gl=f : Then, the
solubility line of the crystal was calculated from the condition
Gc  Gl ¼ ðfc  fÞ@Gl=@f: (4)
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RESULTS AND DISCUSSION
Self-interaction chromatography
Optimization of the SIC methodology
To comply with the theory and assumptions of SIC, 15–20%
surface coverage of the gel particles was found to be the op-
timum for avoiding both multi-body interactions and injection
concentration-dependent retention behavior (22,23,37,42).
An immobilization protein concentration of 9.4 mg of IDEC-
152 per milliliter of packed column corresponds to 15% sur-
face coverage for NHS-activated Sepharose. The incubation
time, temperature, pH, and protein concentration of the im-
mobilization reaction mixture are the parameters by which
the immobilization reaction can be controlled. In this work,
it was found that 12 h of incubation at pH 6.0 and 4C was
sufﬁcient to obtain optimum coupling.
Obtaining injected protein concentration independent reten-
tion behavior is another important requirement in SIC. Our
set-up of a 1.2- to 1.4-ml column, an injection volume of 50
ml, and a MAb concentration of 1–5 mg/ml produced sharp
and detectable peaks. The shape of the peaks showed tailing
due to the mass transfer limitation of large MAb molecules
through the gel pores. The shape of all peaks was the same,
regardless of column type, injection protein concentration or
solution condition. Peak retention was found not to vary with
injection concentration within a range of 1–2.5 mg/ml (Fig. 2).
Therefore, the concentration of MAb in the injection sample
was always kept between 1 and 2 mg/ml and the retention
volume was determined from the peak maximum.
B22 proﬁle of the monoclonal antibody
B22 values of IDEC-152 MAb were mapped as a function of
NaCl concentration at different pH values. Most of the B22
values were found to be in the positive regime up to a NaCl
concentration of 1.0 M at pH 4.5–9.5 (Fig. 3). Very few
points were found to be on the negative side, out of which
none was negative enough to be in the George and Wilson’s
crystallization slot. Since all of the SIC experiments were
performed in a single column, the margin and direction of
inherent error (22,23) in the B22 data must be the same. This
run-to-run error free data suggested a downward peak in B22
at pH 6.5 and 7.6, in which B22 values were minimal at 0.17
M NaCl. The B22 values were slightly negative in these
conditions. Overall B22 mapping in NaCl showed that B22
does not depend much on pH at higher ionic strength. This
simple B22 mapping in NaCl shows why it was impossible to
crystallize IDEC-152 by empirical screening.
In contrast to NaCl, (NH4)2SO4 and PEG are two well-
known precipitants of proteins. Instead of a crystalline solid
phase, amorphous precipitates are often observed in the pres-
ence of (NH4)2SO4 or PEG. B22 values of MAb as a function
of the concentration of these precipitants would also help us
achieve a better understanding of protein phase behavior in
the presence of these precipitants. Both (NH4)2SO4 and PEG-
400 showed similar trends, i.e., an unchanged B22 value up
to 0.6 M (NH4)2SO4 and 15% (v/v) PEG-400 (Fig. 4). Above
these points, the B22 value decreased dramatically to reach
the negative regime of the B22 scale. However, it was im-
possible to run SIC experiments at higher PEG-400 concen-
trations. At PEG-400 concentration of.20% (v/v), the solution
is too viscous to pump through the chromatography column.
On the other hand, the solubility of the MAb was too low to
obtain a well distinguishable peak at an (NH4)2SO4 concen-
tration of .1.0 M.
Phase behavior of the monoclonal antibody
Precipitates of the monoclonal antibody
The solubility of a protein is usually measured by dissolving
crystals in a protein-free solution until the concentration of
FIGURE 2 Effect of the injected protein concentration on the retention of
the MAb. The experiment was conducted at pH 4.2 (100 mM Na-acetate) in
the MAb-immobilized column. FIGURE 3 B22 proﬁle of IDEC-152 in NaCl at different pHs.
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the protein in the liquid phase reaches a constant equilibrium
value. Alternatively it is also possible to start with a super-
saturated solution, in which the solution reaches equilib-
rium through the growth of crystals. It typically takes days
to months to reach equilibrium (67). Both methods were
impossible to implement for IDEC-152, since it has not been
possible to crystallize the MAb yet. Although precipitates are
generally considered as nonequilibrium phases, the residual
protein concentration in the supernatant is widely referred to
as the solubility. In this work, solubility was measured by al-
lowing the MAb solutions to precipitate.
When the solution conditions and the initial MAb con-
centrations were met for the phase separation, precipitates
formed immediately. In some experimental conditions, the
immediately appearing precipitates dissolved during 48 h of
incubation with shaking. The conditions at which the pre-
cipitates did not dissolve showed two distinct phases, a clear
solution phase on the top and a white precipitate phase on the
bottom. Under light microscope, the precipitates were char-
acterized as ﬁbril-like opaque. The obtained precipitates were
reversible, and they could be driven to redissolve by addition
of solvent. The MAb concentration in the supernatant was
found to be independent of the initial protein concentration
within the limits of the experimental error of 10%, consistent
with observations with lysozyme solutions (68,69). In con-
trast, the apparent solubility of a-chymotrypsin, bovine serum
albumin, and bovine liver catalase in precipitation experi-
ments have been reported to be functions of the initial protein
concentration (68,70). The MAb concentration in the super-
natant also showed a smooth decrease with increasing precip-
itant concentrations. However, if the initial MAb concentrations
were too high with respect to the solubility, a sticky gel type
of solid phase was formed. No clear solution could be re-
covered from the top in such circumstances. The character-
istics of IDEC-152 precipitates obtained in NaCl, (NH4)2SO4
or PEG-400 were the same. All of these observations during
the precipitation of IDEC-152 MAb suggest that there is
indeed an equilibrium phase separation, despite the fact that
the precipitates are kinetically trapped nonequilibrium phases.
However, the solubility obtained from the supernatant con-
centration may not be equal to the real equilibrium solubility,
and therefore it is referred to as ‘‘apparent solubility’’ in this
article. Indeed, one would expect a lower supernatant concen-
tration to exist in equilibrium with a crystalline solid phase,
as observed for lysozyme (69,71,72).
Phase diagrams of monoclonal antibody
The apparent solubility and precipitation behavior of IDEC-
152 was studied as a function of the concentration of three
precipitants, NaCl, (NH4)2SO4, and PEG-400, at a constant
temperature of 30C. The apparent solubility was found to
decrease smoothly with increasing precipitant concentration
for all three precipitants, in accordance with Cohn (73). A
series of dilutions was made with varying MAb concentra-
tions around the apparent solubility line. Interestingly, no
phase separation was observed up to a certain concentration
above the apparent solubility line (Fig. 5). The minimum
MAb concentration at which precipitation was observed was
designated as the precipitation line in the phase diagram. The
MAb solution was completely transparent between the sol-
ubility and precipitation lines. It was, however, not possible
to differentiate nucleation and growth region in the super-
saturated area (74) because of unsuccessful crystal growth.
Fig. 5 shows a phase diagram of the IDEC-152 MAb as a
function of NaCl concentration. The solubility of the MAb
was extremely high up to 2.4 M NaCl. A solid phase was
observed at a minimum NaCl concentration of 2.5 M. At
FIGURE 4 B22 proﬁle of IDEC-152 in (NH4)2SO4 and PEG-400 at
pH 7.6.
FIGURE 5 Phase behavior of IDEC-152 MAb in NaCl at 30C and
pH 7.6.
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4.5 M NaCl, the solubility of the MAb was extremely low
(,1 mg/ml). Phase diagrams were obtained in similar
fashion for (NH4)2SO4 (Fig. 6) and PEG-400 (Fig. 7).
MAb in the framework of universal phase diagram
In this work, phase diagrams of IDEC-152 MAb were ob-
tained as a function of precipitant concentration at a constant
temperature of 30C. One would expect protein phase be-
havior as a function of a precipitant concentration to be simi-
lar to that of the inverse of temperature. However, measurement
of the liquid-liquid coexistence curve as a function of pre-
cipitant concentration is extremely difﬁcult by the cloud-
point method (75,76), because of the difﬁculty of slowly
increasing or decreasing the precipitant concentration while
keeping all other parameters constant. In addition, the source
of the turbidity in IDEC-152 solutions was mostly due to the
formation of precipitates, unlike the liquid droplets observed
in a previous study (76). However, Lenhoff and co-workers
(69) showed that the supernatant curve of lysozyme obtained
from precipitation and cloud-point measurements is consis-
tent with the low-density branch of the metastable liquid-
liquid coexistence curve. On the other hand, the formation of
the dense branch of the liquid-liquid binodal is perturbed by
the appearance of ﬂocks or aggregates. Therefore, gels or
precipitates represent a different, but kinetically trapped, struc-
ture for the dense liquid phase. The physical appearance of
the lysozyme precipitate described in Cheng et al. (69) was
similar to that observed in this study. In both cases, the pre-
cipitates were opaque and settled at the bottom of the tube. If
shaken, it caused the solution to be turbid. The liquid phase
concentration was independent of initial protein load, con-
forming to the pseudoequilibrium. Furthermore, the initial
higher load of protein caused the formation of gel in both
cases. Therefore, precipitates of MAb can be interpreted as
the dense branch of the liquid-liquid binodal. In that case, the
dense phase in the liquid-liquid phase separation must be
similar to the dense liquid phase described by Prausnitz and
co-workers (68,77,78), where precipitates were named as
dense liquid phases and protein was treated as the partition-
ing solute between the liquid and precipitate phases.
A generic format of phase diagrams was made with the
above assumptions. The concentration of MAb in both the
supernatant phase (apparent solubility) and the precipitate
(dense) phase was plotted against the reverse scale of the
(NH4)2SO4 concentration (Fig. 8). The supernatant and pre-
cipitate MAb concentrations show an apparent equilibrium
curve, which represents the liquid-liquid coexistence curve.
FIGURE 6 Phase behavior of IDEC-152 MAb in (NH4)2SO4 at 30C and
pH 7.6
FIGURE 7 Phase behavior of IDEC-152 MAb in PEG-400 at 30C and
pH 7.6.
FIGURE 8 Phase diagram of IDEC-152 MAb showing liquid-liquid
coexistence.
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Since the crystal-liquid equilibrium solubility curve could
not be determined experimentally, the position of the liquid-
liquid co-existence curve with respect to the solubility curve
cannot be shown directly. However, the position of the
liquid-liquid co-existence curve can be visualized by plotting
it against B22. Such a phase diagram was generated in B22
scale according to the model described by Haas and Drenth
(51–53). The calculated phase diagram (Fig. 9) shows that
the critical point is located at a B22 value of –0.32 3 10
4
mol ml/g2, which corresponds to slightly negative B22 values
of George and Wilson’s crystallization slot (20,21). There-
fore, the calculated phase diagram of MAb is consistent with
the fact that the precise location of the nucleation is around
the critical point. The crystal-liquid solubility line (Fig. 9,
dashed line) is equal to the light branch of the bimodal, for an
f value of .0.3217. The phase diagram of MAb is therefore
more likely to exhibit a triple point than an isolated crystal-
liquid solubility line.
The experimentally determined liquid-liquid coexistence
curve in (NH4)2SO4 concentration scale was transformed
into the B22 scale by interpolation, since the B22 values were
known as a function of (NH4)2SO4 concentration. The ex-
perimental data points of liquid-liquid coexistence are shown
in Fig. 9. Although the light branch of the data points matched
well with the spinodal, the dense branch showed much lower
concentration than theoretical expectation. This is because
precipitates are considered the dense phase and the precise
determination of the precipitate volume and concentration is
difﬁcult. However, the above observations suggest that the
MAb, a complex glycoprotein, certainly supports the so-called
universal format of phase diagram.
The question arises: why is crystallization of IDEC-152
MAb impossible when the phase diagram supports a generic
format? It is obvious from the phase diagram (Fig. 9) that
spontaneous classical homogeneous nucleation just above
the critical point is not possible for two reasons. First, the
critical point corresponds to a protein volume fraction of
0.131 or a concentration of 188 mg/ml. Conducting crystal-
lization experiments above such a high protein concentration
is impractical and inapplicable. Second, there is insufﬁcient
or no space between the liquid-liquid critical point and the
solubility line. The only possible mechanism remaining for
nucleation of the MAb is the liquid-liquid phase separation.
Therefore, crystallization of MAb is only expected between
the light branch of the binodal and spinodal, which might
be a very narrow range. A possible reason for unsuccess-
ful crystallization is that even if an experiment is designed
between the light branch of the binodal and spinodal, the
crystallization process itself might be too slow for crystals to
form within a practical time frame. A third reason for unsuc-
cessful crystallization could be the shape of the MAb mole-
cule. A slightly negative B22 value around 0.8 M (NH4)2SO4
could be due to strong attractions in a few speciﬁc orien-
tations that are not favorable to solid lattice formation.
CONCLUSION
The work presented here shows a phase behavior study of a
complex glycoprotein. Like most well studied proteins, phase
behavior of IDEC-152 MAb shows a behavior of decreasing
solubility with increasing precipitant concentration, accord-
ing to Cohn (76). Rescaling of the phase diagram in B22 units
shows that spontaneous classical homogeneous nucleation
of MAb crystals is not possible just above the liquid-liquid
critical point, because of insufﬁcient or no space between the
critical point and the solubility line. Nucleation of IDEC-152
MAb could only be possible by liquid-liquid phase separa-
tion in a narrow window. However, the idea of a universal
protein phase diagram was supported for this large complex
glycoprotein. Further study is required on uncommon and
structurally complex proteins to understand protein phase
behavior in a generalized way. This study further concludes
that the crystallization of proteins in (NH4)2SO4 is rather
difﬁcult, because both solubility and B22 decrease drastically
above a certain (NH4)2SO4 concentration, leaving an ex-
tremely narrow window of crystallization.
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